Debra Hughes, MS

Debra (Lumpe) Hughes has more than 3 decades of oncology medical writing and editing experience, including as a former editor of Oncology Times. She has a diverse background in medical journalism, education, and publishing. Her company, D.A. Hughes & Associates, provides medical communications services for academic institutions, communications and publishing companies, global pharmaceutical and biotechnology corporations, and professional medical associations and societies. Debra is an alumna of Columbia University Graduate School of Journalism, where she specialized in science writing, and the University of California, Riverside.

Most Recent Articles by Debra Hughes, MS

Q&A With Adam M. Brufsky, MD, PhD: Endocrine-based Therapy for HR-positive Metastatic Breast Cancer

Q&A With Adam M. Brufsky, MD, PhD: Endocrine-based Therapy for HR-positive Metastatic Breast Cancer

By

Cancer Therapy Advisor asked Dr Brufsky to comment on the evolving role of endocrine-based therapy for this patient population, including combinations based on molecular and genetic profiling.

Q&A With Dr Shaji Kumar: Ameliorating Bortezomib-induced Peripheral Neuropathy

Q&A With Dr Shaji Kumar: Ameliorating Bortezomib-induced Peripheral Neuropathy

By

Cancer Therapy Advisor asked Dr Kumar to discuss his team's investigation into a dexamethasone dosing schedule for reducing the rates of peripheral neuropathy.

Q&A With Dr Shaw: ALK/ROS1 Inhibition in Patients With Non-small Cell Lung Cancer

Q&A With Dr Shaw: ALK/ROS1 Inhibition in Patients With Non-small Cell Lung Cancer

By

Cancer Therapy Advisor asked Dr Shaw to discuss ALK- and ROS1-positive NSCLC, including currently available agents and ongoing research to develop additional targeted therapies.

Q&A With Filippo Montemurro, MD: Considerations for Treatment With Trastuzumab Emtansine

Q&A With Filippo Montemurro, MD: Considerations for Treatment With Trastuzumab Emtansine

By

Cancer Therapy Advisor asked Filippo Montemurro, MD, to place recent findings in context with respect to when T-DM1 might be best indicated.

Q&A With Michael A. Dyer, MD: Unraveling the Retinoblastoma Epigenome

Q&A With Michael A. Dyer, MD: Unraveling the Retinoblastoma Epigenome

By

Cancer Therapy Advisor interviewed Dr Dyer about recent study results relating to the retinoblastoma epigenome and an important finding about the timing of retinoblastoma development.

More Articles by Debra Hughes, MS

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters